Fourth quarter and full year 2022 financial results and business update

Copenhagen, denmark, april 27, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, announced today the fourth quarter and full-year 2022 financial results and provided a business update.

EVAX Ratings Summary

EVAX Quant Ranking